Streetbeat News

Analyst Ratings

EVGN

Alliance Global Partners analyst Ben Haynor has initiated coverage on Evogene (NASDAQ:EVGN) with a Buy rating and a price target of $1.85.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:24 pm

SPY

In a recent CNBC interview, Bill Ackman, a well-known hedge fund manager, stated that he believes the economy is beginning to slow down and that the Federal Reserve is likely done with its rate hikes.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:22 pm

CC

FMC

WRK

Three high-dividend yield materials stocks, WestRock Company (WRK), FMC Corporation (FMC), and The Chemours Company (CC), have been recommended by Wall Street's most accurate analysts. WestRock, with a dividend yield of 3.07%, is merging with Smurfit Kappa Group to form a sustainable packaging company. FMC, yielding 3.46%, reported weaker-than-expected Q2 results. Chemours, with a yield of 3.57%, posted better-than-expected Q2 earnings.

Portfolio Pulse from Lisa Levin

October 02, 2023 | 12:22 pm

CCL

William Blair analyst Sharon Zackfia has reinstated Carnival (NYSE:CCL) with an Outperform rating.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:22 pm

META

SNAP

TSLA

In a recent CNBC interview, Bill Ackman stated that social media platform X has significantly improved and is likely to see a return of advertisers. Although META, SNAP, and TSLA were mentioned in the article, it's unclear if they are directly related to platform X.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:14 pm

HZNP

Horizon Therapeutics (NASDAQ:HZNP) has announced that new analyses of its drug UPLIZNA will be presented at the 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2023. UPLIZNA is the first and only targeted CD19+ B-cell-depleting therapy approved by the FDA, the European Commission, and the Brazilian Health Regulatory Agency for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) in adults.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:14 pm

BBAI

TD Cowen analyst Shaul Eyal has initiated coverage on BigBear.ai Hldgs (NYSE:BBAI) with a Market Perform rating and a price target of $2.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:13 pm

SASR

DA Davidson analyst Manuel Navas has downgraded Sandy Spring Bancorp (NASDAQ:SASR) from Buy to Neutral and lowered the price target from $28 to $22.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:10 pm

NSC

B of A Securities analyst Ken Hoexter has downgraded Norfolk Southern (NYSE:NSC) from Buy to Neutral and lowered the price target from $266 to $215.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:07 pm

PDSB

PDS Biotech has announced that its lead candidate PDS0101, when combined with standard-of-care chemoradiotherapy, was associated with a rapid decline in human papillomavirus (HPV) circulating cell-free DNA, a potential predictive biomarker of treatment response. The data was presented at the ASTRO 2023 Annual Meeting. The study evaluated the relationship between the levels of circulating cfHPV-DNA and the extent of disease, clinical staging, and treatment response in patients with HPV-positive cervical cancer.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:06 pm